Maresin1 (MaR1) is a new docosahexaenoic acid-derived pro-resolving agent that promotes the resolution of inflammation. In this study, we sought to investigate the effect and underlining mechanisms of MaR1 in modulating alveolar fluid clearance (AFC) on LPS-induced acute lung injury. MaR1 was injected intravenously or administered by instillation (200 ng/kg) 8 h after LPS (14 mg/kg) administration and AFC was measured in live rats. In primary rat alveolar type II epithelial cells, MaR1 (100 nM) was added to the culture medium with lipopolysaccharide for 6 h. MaR1 markedly stimulated AFC in LPS-induced lung injury, with the outcome of decreased pulmonary edema and lung injury. In addition, rat lung tissue protein was isolated after intervention, and we found MaR1 improved epithelial sodium channel (ENaC), Na, K-adenosine triphosphatase (ATPase) protein expression and Na,K-ATPase activity. MaR1 down-regulated Nedd4-2 protein expression though PI3k/Akt but not though PI3k/SGK1 pathway in vivo. In primary rat alveolar type II epithelial cells stimulated with LPS, MaR1-upregulated ENaC and Na,K-ATPase protein abundance in the plasma membrane. Finally, the lipoxin A4 Receptor inhibitor (BOC-2) and PI3K inhibitor (LY294002) not only blocked MaR1's effects on cAMP/cGMP, the expression of phosphorylated Akt and Nedd4-2, but also inhibited the effect of MaR1 on AFC in vivo. In conclusion, MaR1 stimulates AFC through a mechanism partly dependent on alveolar epithelial ENaC and Na,K-ATPase activation via the ALX/PI3K/Nedd4-2 signaling pathway. Our findings reveal a novel mechanism for pulmonary edema fluid reabsorption and MaR1 may provide a new therapy for the resolution of ALI/ARDS.
Acute respiratory distress syndrome (ARDS), characterized by alveolar edema which impairs gas exchange, is a devastating condition with 35-45% mortality rate. 1, 2 However, there is currently no specific pharmacotherapy to reduce injury or enhance resolution in clinical ARDS patients. 3 Hence, innovative therapies are needed to decrease the mortality. 4 Earlier reports have shown that reduced alveolar fluid clearance (AFC) was a characteristic feature of ARDS. 5 As a result, removal of excessive alveolar edema fluid is an important way for effective treatment and better outcome. 6 AFC represents alveolar filling and clearance. 7 It has been generally believed that epithelial sodium channel (ENaC) is the primary determinant of AFC, a driving force to remove edema fluid from alveolar spaces on the ion transportdependent mechanism. 8 Na + ions enter alveolar typeII epithelial (ATII) cells at the apical surface primarily through amiloride-sensitive sodium channels and are pumped out on the basolateral surface by Na,K-ATPase (sodium pump). This solute transport drives osmotic water transport. 9 ENaC is composed of α, β, and γ subunits. The three subunits of ENaC are all indispensable for efficient AFC. 10 Neonatal α-ENaC gene knockout mice developed respiratory distress and died within 40 h of birth because of failing to clear the alveolar fluid. 11 Na,K-ATPase inhibition with ouabain reduces the short circuit current across alveolar typeII cells, and markedly decreased solute and fluid transport in alveoli. 12 Many studies have shown that angiotensin, 7 Triiodo-L thyronine, 9 Estradiol, 13 enhanced AFC via increasing ENaC activity or increasing Na,K-ATPase activity. However, these have failed to translate positively in human studies. 14 In addition, our previous studies found that intravenous injection β-agonists (salbutamol) reduced extravascular lung water in ARDS patients, but did not improve the clinical outcome. [15] [16] [17] [18] Maresins are novel macrophage mediators with potent anti-inflammatory and pro-resolving actions. 19 They are biosynthesized via 12-lipoxygenase in humans to generate 14 S-hydroperoxydocosa-4Z,7Z,10Z,12E,16Z,19Z-hexaenoic acid, which undergoes further conversion to 13(14) -epoxidation and is subsequently converted to 7,14-dihydroxydocosa-4Z,8Z,10,12,16Z,19Z-hexaenoic acid, known as maresin1 (MaR1). 20 Maresin1 proved to be a potent mediator by stopping polymorphonuclear infiltration and stimulating macrophages phagocytosis. 21, 22 Previous data from our group suggested that both resolvin D1 (ref. 23 ) and lipoxin A4 (ref. 24 ) activated alveolar epithelial sodium channel, Na, K-ATPase, and increased AFC. However, so far there are no studies about the effects and mechanisms underlying the actions of MaR1 on pulmonary edema.
This study was designed to investigate whether MaR1 could exert protective effects on AFC in LPS-induced ALI. In addition, we investigated the effect of MaR1 on the protein expression of ENaC, Na,K-ATPase, SGK1, Akt and Nedd4-2, and the activity of Na,K-ATPase. Finally, to better understand the mechanisms of action of MaR1, we used ALX receptor inhibitor (BOC-2) and PI3K inhibitor (LY294002) to investigate how this signaling pathway regulated ENaC and AFC.
MATERIALS AND METHODS Materials 7(R)-MaR1 and LY294002 (PI3K inhibitor) were from Cayman Chemical Company (Ann Arbor, MI, USA). LPS (Escherichia coli serotype 055:B5) was purchased from Sigma (St Louis, MO, USA). Myeloperoxidase (MPO), TNF-α, IL-10, cAMP, cGMP ELISA kits were from R&D Systems (Minneapolis, MN, USA). BOC-2 (ALX inhibitor) was obtained from Biomol-Enzo Life Sciences (Farmingdale). Anti-ENaC-α, β, γ, anti-Na,K-ATPase-α1, β1, anti-P-SGK1 (ser 422 ), anti-total-SGK1 were purchased from Abcam (Cambridge, MA, USA). Anti-P-Akt 473 and anti-total-Akt were purchased from Cell Signalling Technology (Cell Signaling Technology, Danvers, MA, USA).
Animal Preparation
Adult male Sprague-Dawley rats were used to perform experiments (280-320 g, Shanghai Experimental Animal Center of China). The use of animals in this study was approved by the Animal Studies Ethics Committees of the Second Affiliated Hospital of Wenzhou Medical University.
Rats were randomly divided into six groups (n = 8): control group, LPS group, LPS+MaR1 (intravenous, i.v.) group, LPS +MaR1 (instill) group, MaR1 (i.v.) group, MaR1 (instill) group. The LPS-induced lung injury model was produced by 14 mg/kg LPS injected via caudal vein. In the MaR1 (i.v.) group or the MaR1 (instill) group, rats received MaR1 (200 ng/kg) i.v. via caudal or via instillation. In other groups, rats received MaR1 or alcohol or equivalent volume of saline (the control group) via caudal vein 8 h after LPS exposure. Animals were anesthetized with an intraperitoneal (i.p.) injection of 5% chloral hydrate (7 mg/kg), after which a tracheotomy tube was placed. Rats were sacrificed after 60 min of mechanical ventilation and lungs were collected.
Pathological Studies
The right lower lung lobes were collected and fixed with 10% neutral-buffered formalin for 24 h, then embedded in paraffin and stained with H&E for light microscope analysis. A semiquantitative scoring system was adopted to evaluate the lung injury including alveolar congestion, alveolar hemorrhage, infiltration or aggregation of neutrophils in the airspace or vessel wall, and thickness of alveolar wall/hyaline membrane formation and inflammatory cell infiltration. The grading scale to score the pathologic findings was as follows: 0 = no injury; 1 = slight injury (25%); 2 = moderate injury (50%); 3 = severe injury (75%); and 4 = very severe injury (almost 100%). The results were graded from 0 to 4 for each item, as described previously. 25 The four variables were summed to represent the lung injury score (total score: 0-16). Part of the right lung was homogenized from individual rats and centrifuged, and the tissue level of MPO, TNF-α, IL-10 in the resulting supernatants was, respectively, determined using a rat MPO ELISA kit, a rat TNF-α ELISA kit, a rat IL-10 ELISA kit.
Measurement of AFC in Live Rats
AFC was measured in living rats as previously described 9, 26, 27 with some modifications. Clearance is expressed as a percentage of total instilled volume cleared after 60 min. AFC was determined by Evans blue-tagged albumin concentration changes, which has been clearly characterized by our laboratory. 24 For preparation of the alveolar instilled solution, a 5% albumin-instilled solution was prepared by dissolving 50 mg/ ml BSA in modified lactated Ringer's solution: 137 mM NaCl, 4.67 mM KCl, 1.82 mM CaCl 2 × 2H 2 O, 1.25 mM MgSO 4 × 7 H 2 O, 5.55 mM dextrose, and 12 mM HEPES. The pH was adjusted to 7.4 at 37°C. The albumin solution was labeled with 0.15 mg/ml Evans blue. In brief, after anesthesia with 5% chloral hydrate (7 ml/kg), a polyethylene endotracheal tube was inserted through a tracheotomy. Rats were ventilated with a constant volume ventilator (model HX-300 Animal ventilators; Taimeng Company of Chengdu, China) with an inspired oxygen fraction of 100%, a respiratory rate of 45-50 breaths per min and 2.86 ± 0.2 ml tidal volumes, positive end expiratory pressure was kept at 2-3 cm H 2 O during the baseline period. After tracheotomy, the rats were allowed to stabilize for 10 min. The animals were then placed in the left lateral decubitus position, and instillation tubing (16G Epidural catheter) was gently passed through the tracheotomy tube into the left lung. A total of 1.5 ml (5 ml/kg) of the instilled solution was instilled at a rate of 0.08 ml/min using a syringe pump. After instillation was complete, 0.2 ml air was injected to clear the instillation catheter of liquid. The instillate remaining in the syringe was collected as the initial sample. After instillation, the catheter was left in place for duration of 60 min. The final alveolar sample was collected via the instillation catheter. The concentrations of Evans bluelabeled albumin in the instilled and aspirated solutions were measured by a spectrophotometer at a wavelength of 621 nm. AFC was calculated using the following equation: AFC = (1 − C 0 /C 1 ), where C 0 is the protein concentration of the instillate before instillation, and C 1 is the protein concentration of the sample obtained at the end of 60 min of mechanical ventilation.
Evaluation of Pulmonary Edema
The lower lobes of the right lung from each group were assessed for dry/wet weight ratios. The remaining lung tissues were collected for further analysis and stored at − 80°C.
Primary Rat ATII Cells Isolation, Culture, and Treatment Primary rat ATII cells were isolated from Sprague-Dawley rats (200-250 g) by elastase digestion of lung tissue and then differentially adhered on IgG-coated plates as described by Dobbs et al. 28 The purity of ATII cells was assessed by modified Papanicolaou stain based on the presence of dark blue inclusions. Cell viability was assessed by trypan blue exclusion (495%). ATII cells were seeded onto plastic culture dishes at 1 × 10 6 /cm 2 and cultured in a 5% CO 2 , 95% air atmosphere in DMEM containing 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin, and 0.1 mg/ml streptomycin after isolation. For all experiments, cells were subcultured into six-well plates and maintained until sub-confluence (80%), and cells were serum deprived for 24 h before the addition of LPS (1 μg/ml) in the presence or absence of MaR1 (100 nM).
Western Blotting for ENaC, NaN, K-ATPase, Akt, SGK1, and Nedd4-2 Proteins were obtained with RIPA lysis buffer (50 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-100,1% sodium deoxycholate, 0.1% SDS, sodium orthovanadate, sodium fluoride, EDTA, and leupeptin) and PMSF. Samples were ultrasonicated three times, for 5 s, and then spun at 12 000 g per min for 30 min. Protein concentrations of the supernatants were determined by using a BCA protein assay kit (Thermo Scientific, Rockford, IL, USA). Proteins were separated by 10% SDS polyacrylamide gels and transferred to PVDF membranes. After blocking with 5% nonfat dried milk in TBS containing 0.05% Tween 20, the membranes were incubated with primary Abs ENaC-α, β, γ (1:500, 1:1000, 1:3000), Na,K-ATPase-α1, β1 (1:1000), and β-actin (internal control, 1:500), Akt (1:2000), SGK1 (1:500), phosphor Akt (1:1000) and phospho SGK1 (1:1000), Nedd4-2 (1:5000) overnight at 4°C, and then reacted with HRP-conjugated secondary Ab (1:1000; Santa Cruz Company) at room temperature for 1.5 h. The protein bands were detected by ECL and visualized by UVP Gel imaging system (Upland, CA, USA). The band intensity was analyzed by AlphaEaseFC (version 4.0).
Confocal Imaging
ATII cells were respectively treated with saline, LPS (1μg/ml), LPS+MaR1 (100 nM), and MaR1 for 12 h after fixing in 4% paraformaldehyde and blocked with PBS containing 10% donkey serum for 30 min. The cells were then incubated in a 1:50 dilution of monoclonal mouse anti-Na,K-ATPase and goat anti-ENaC-α at 4°C for 48 h, followed by Alexa Fluor donkey anti-goat and donkey anti-mouse IgG incubation (1:100 and 1:300; Jackson) at room temperature for 2 h. Cell images were acquired with confocal laser-scanning microscope (Leica) and analyzed by Image Pro plus 6.3 software (Media Cybernetics, Q: 13MA).
Measurement of Na,K-ATPase Activity in Rat Lung Tissues
The hydrolytic activity of Na,K-ATPase was measured as ouabain-sensitive ATP hydrolysis under maximal velocity conditions by measuring the release of inorganic phosphate from ATP, as previously described. 29 In brief, the rat lung tissues were digested, subjected to centrifugal sedimentation, lysed, and homogenized. The minimal ATP enzyme test kit (Jiancheng Company, Nanjing, China) was used to assay Na, K-ATPase activity following manufacturer's instructions.
Measurement of cAMP and cGMP Concentrations cAMP and cGMP concentration in cell lysates and in lung tissue homogenate were measured via ELISA kits according to the manufacturer's instructions.
Statistical Analyses
Data are represented as mean ± s.e.m. All data were analyzed by the Student t-test or by one-way ANOVA followed by Tukey's post-hoc test for multiple comparisons. Significance was determined at the Po0.05 level. Statistical analyses were performed using Prism 5.0 software (GraphPad Software, San Diego, CA, USA).
Results
MaR1 Alleviated LPS-induced ALI First, we evaluated the effect of MaR1 on LPS-induced ALI. The control group revealed normal pulmonary histology (Figure 1a) . Compared with the control group, lung tissues in the LPS group were significantly damaged with interstitial edema, hemorrhage, and inflammatory cells infiltration as evidenced by an increase in lung injury score (Po0.01). All the morphologic changes were less pronounced in the LPS +MaR1 (i.v.) group and in the LPS+MaR1 (instill) group. MaR1 significantly attenuated LPS-induced pathologic changes by the evidence of a decrease in lung injury score (Po0.01). There was no significant difference between the control and MaR1 groups ( Figure 1b) .
Next, lung tissues homogenate MPO, TNF-α, and IL-10 concentration were analyzed. The concentration of MPO, TNF-α, and IL-10 were significantly increased in the LPS group compared with the control group (Po0.01), but greatly attenuated in the MaR1 treatment group compared with the LPS group (Po0.01; Figures 2a-c) .
MaR1-Upregulated AFC in LPS-Induced ALI In Vivo As shown in Figure 3a , the effect of LPS on AFC was doseresponse relationship. Next, we examined the effect of MaR1 on AFC in LPS-induced ALI in vivo. MaR1 at a concentration of 200 ng/kg was injected through caudal vein or through alveolar instillation 8 h after LPS (14 mg/kg) administration, and AFC was determined after 60 min. AFC in the LPS group was as expected, reduced compared with the control group (Po0.01), whereas MaR1 increased AFC after LPS-challenged ALI (Po0.05 or Po0.01). Moreover, there was significant increase in MaR1 (instill) group (Po0.05 versus control group; Figure 3b ). In contrast, AFC in the amiloride group was reduced compared with the control group (Po0.01), whereas MaR1 cannot increased AFC after amiloridechallenged (Po0.01; Figure 3c ).
MaR1 Attenuated Pulmonary Edema
We examined pulmonary edema by measuring lung wet/dry weight ratios. Figure 4 shows a significant increase in the wet/ dry weight ratio in the LPS group compared with the control group (Po0.01). In contrast, the wet/dry ratios in the LPS +MaR1 (i.v.) and LPS+MaR1 (instill) group were lower than the LPS group (Po0.01).
MaR1 Enhanced ENaC in LPS-Induced ALI In Vivo
To clarify whether MaR1 effects on AFC are mediated by ENaC, the protein was isolated from rat lungs and measured by western blotting. As shown in Figure 5 , the protein expression of ENaC-α and γ subunits in rat lung tissue homogenates were increased in the LPS+MaR1 (i.v.) group compared with the LPS group (Po0.01) and the protein expression of ENaC-γ in rat lung tissue homogenates was increased in the LPS+MaR1 (instill) group compared with the LPS group (Po0.01). However, no significant change in protein expression of ENaC-β subunit was observed after treatment with MaR1 (P40.05; Figure 5 ).
MaR1-Upregulated Na,K-ATPase in LPS-Induced ALI In Vivo As shown in Figure 6a , the protein expression of Na,KATPase β1 subunit in rat lung tissue homogenates was increased in the LPS+MaR1 (i.v.) group and LPS+MaR1 (instill) group compared with the LPS group (Po0.01). However, no significant change in protein expression of Na, K-ATPase-α1 subunit was observed after treatment with MaR1 (P40.05; Figure 6a ).
As shown in Figure 6b , the Na,K-ATPase activity in the LPS group was markedly decreased compared with the control group (Po0.01), whereas MaR1 augmented Na,K-ATPase activity after LPS-induced ALI (Po0.01).
Dose and Time Dependency MaR1 Regulated Na,KATPase-β1 Expression in Primary ATII Cells Western blotting was used to determine the dose-response and temporal expression patterns relationship of MaR1 regulating Na,K-ATPase-β1 subunit expression. Incubating with the different concentrations of MaR1 including 1, 10, 50, and 100 nM with cells. As shown in Figure 7a , the Na,KATPase-β1 subunit expression was increased dosedependently with a concentration of 100 nM producing a maximal effect. In subsequent experiments, the ENaC and Na,K-ATPase expression in ATII cells was assessed using 100 nM MaR1 (Figure 7a) .
In Figure 7b showed the dynamic expression of Na,KATPase-β1 subunit in primaryII cells. The expression of Na, MaR1 Increased ENaC and Na,K-ATPase Protein Abundance in the Plasma Membrane in Primary ATII Cells Confocal laser-scanning microscopy further examined the effect of MaR1 on the subcellular distribution of the ENaC-α and Na,K-ATPase-α. MaR1 significantly increased ENaC-α abundance in the plasma membrane compared with the LPS group (Figure 8a) . Moreover, MaR1 significantly increased Na,K-ATPase-α abundance in the plasma membrane compared with the LPS group (Figure 8b ). These results of microscopic images were consistent with immunohistochemistry of rat lung tissues.
MaR1-Induced cAMP and cGMP Elevation Stimulated with LPS In Vivo and Vitro was Dependent on ALX
To test whether MaR1 (100 nM) has an impact on cAMP and cGMP levels in ATII cells, we measured cAMP and cGMP Figure 10a ). Nevertheless, no significant change in the protein level of phosphorylated SGK1 was observed (Figure 10b ). Nedd4-2, an E3 ubiquitin-protein ligase, is critical in the negative control of Na + transport. To further investigated the effect of MaR1 on Nedd4-2, the protein expression of Nedd4-2 in rat lung tissue homogenates was measured by western blotting. The protein level of Nedd4-2 in LPS group was significantly increased compared with the control group (Po0.05) and significantly decreased in the MaR1 treatment group compared with the LPS group (Po0.05). However, the protein level of Nedd4-2 in LPS+MaR1+BOC-2 group and in LPS+MaR1+LY294002 group was significantly increased compared with the LPS+MaR1 group (Figure 10d ). The dose-and temporal-dependent changes of Na,K-ATPase protein expression in primary ATII cells stimulated with LPS (1μg/ml) were determined by western blotting. Western blot data were replicated 43 times. Cells were incubated with different concentrations of MaR1 for 6 h including 1, 10, 50, and 100 nM to measure the Na,K-ATPase-β1 subunit protein expression (a). Moreover, ATII cells were incubated with LPS (1 μg/ml) for 1, 2, 4, and 6 h to detect the expression of Na,K-ATPase-β1 subunit protein (b). 
DISCUSSION
In this study, we provide evidence for the pro-resolution activity of MaR1 in ARDS. Treatment with MaR1 improved AFC and decreased pulmonary edema and lung injury in LPSinduced ALI in rats. MaR1 most potently regulated AFC with up-regulating the protein expression of ENaC and Na,KATPase increasing the activity of Na,K-ATPase in vivo and in vitro. MaR1 enhanced the subcellular distribution of ENaC and Na,K-ATPase, specifically localized to the apical and basal membrane of the alveolar epithelium. Moreover, BOC-2 and LY294002 blocked the increased AFC response to MaR1. MaR1-induced decrease Nedd4-2 was blocked with BOC-2 and LY294002 treatment, respectively, in vivo, indicating MaR1 increased ENaC and Na,K-ATPase expression to promote AFC via the ALX/PI3K/Nedd4-2 signaling pathway. Acute lung injury is characterized by the disruption of the alveolar epithelial barrier, which results in increased edema formation, as well as impaired edema clearance. 30 It is widely accepted that resolution of alveolar edema is associated with improved oxygenation, shorter duration of mechanical ventilation, and increased likelihood of survival. 31, 32 Our data clearly demonstrate that MaR1 significantly attenuated pulmonary edema and improved the air-blood barrier. Furthermore, MaR1 both administered intratracheally and intravenously enhance the rate of AFC 8 h after LPS challenge with the outcome of decreased pulmonary edema, suggesting that MaR1 has a role in the resolution of inflammation. Interestingly, MaR1 has no influence on AFC when administered intravenously, but improved AFC when administrated intratracheally in healthy intact rats. Our results demonstrated that ENaC inhibitor totally abolished the effects of MaR1 indicating ENaC was major mechanism of MaR1. However, our results showed instilled MaR1 had no effect on the protein expression of ENaC and Na,K-ATPase, the mechanisms were under investigated.
The primary force driving fluid reabsorption from the alveolar space into the interstitium and the pulmonary circulation is active Na + transport, which leads to an osmotic gradient that drives the movement of fluid from the alveolar space back into the interstitium and eventually to the blood circulation. 33 Several observations confirm that transepithelial sodium transport has a major role in the clearance of fluid from the airspace. 30 In our study, MaR1 not only enhanced lung tissues homogenate ENaC protein expression in LPSinduced ALI, but also increased ENaC protein abundance in the plasma membrane in primary ATII cells stimulated with LPS. Consistent with our findings, similar results have shown that upregulation of ENaC increased pulmonary edema fluid reabsorption and reduced ENaC expression delayed reabsorption of fluid during pulmonary edema after thiourea-induced lung injury. 32, 34 These findings, therefore, suggest that MaR1 promotes AFC through upregulation of ENaC protein expression, and increasing EnaC protein abundance in the plasma membrane.
The sodium pump (Na,K-ATPase) located on the basolateral surface of the alveolar epithelial cell transports ions by Figure 8 MaR1 increased ENaC and Na,K-ATPase protein abundance in the plasma membrane in primary ATII cells stimulated with LPS. Rat primary ATII cells were treated with MaR1 (100 nM) in the presence or absence of LPS (1 μg/ml) for 6 h. The effect of MaR1 on the subcellular distribution of the ENaC-α (a) and Na,K-ATPase-α (b) were examined by confocal laser-scanning microscopy using a specific Ab against (original magnification × 400). Alexa Fluor second Ab was used to stain the cells.
Maresin1 stimulates alveolar fluid clearance J-L Zhang et al consuming ATP and pumping Na + out of the cell in exchange for potassium influx to maintain Na + and potassium gradients across the plasma membrane. 35 The basolateral membrane location of the Na,K-ATPase is crucial for alveolar fluid reabsorption where the vectorial Na + transport is followed by water in an isosmolar manner. 14, 30, 36 It has been well established that upregulation of ENaC and Na,K-ATPase increases active Na + transport, leading to increased ability of the lungs to clear edema. 30, 37 Impairment of Na,K-ATPase function appears to be a hallmark during lung injury even in a preclinical stage. 30, 35, 38 In our study, we demonstrated that MaR1 not only increased Na,K-ATPase expression in rat lung tissues and primary ATII cells after LPS challenge by western blotting, immunohistochemistry, and confocal laser-scanning microscopy measurement, but also upregulation of Na,KATPase activity in vivo. Altogether, our data from the lung tissues and cell culture indicate that MaR1 promotes AFC through both of the essential mechanisms of ENaC and Na,K-ATPase.
Specialized pro-resolving lipid mediators (SPMs) derived fromv-3 polyunsaturated fatty acids orchestrate resolution in diverse settings of acute inflammation. 39 Maresin1 is one of family of SPMs displaying potent anti-inflammatory and proresolving actions. 21, 40 However, so far the receptors and downstream signalling pathways of MaR1 are under investigated. It has been generally believed that the SPMs exert their actions by interacting with G-protein-coupled receptor (GPCR) with high affinity and stereospecificity. 22, 41 ALX (lipoxin A4 receptor) is a GPCR with cell-type-specific signaling pathways. 42, 43 cAMP and cGMP are important second messengers by which cells extracellular signals into intracellular responses. 23 Extracellular signals interact with GPCRs to activate the AC and increase the intracellular cAMP and cGMP levels. A previous study showed that LPS-induced immune response leads to a decrease of intracellular cAMP. 44 Another study pointed out cGMP-activated Na + channels is a novel pathway for resolving fluid in injured lungs. 45, 46 Against this background, our purpose was to evaluate whether the role of MaR1 on lung is ALX/cAMP/cGMP dependent. Our studies illustrated that the intracellular cAMP and cGMP level was decreased after LPS stimulation, and MaR1 abrogated the decrease observed in the LPS group in vitro and in vitro. Furthermore, we found that MaR1-induced increase in the levels of cAMP and cGMP were blocked with BOC-2 (ALX antagonist), not with LY294002 (PI3K inhibitor). Moreover, BOC-2 blocked the increased AFC in MaR1 treatment group. These results, taken together, suggest that the MaR1 response is ALX/cAMP/cGMP dependent.
It is well-known that PI3K signals are implicated in regulating ENaC trafficking and activity. 47 The PI3K has been identified for regulation of ENaC-mediated AFC by insulin. 8 The signaling cascade downstream of PI3K involves of several effector proteins. One is Akt, which is believed to be the central mediator of signaling with profound effects on several physiological events. 48, 49 The other candidate for the effector proteins downstream of PI3K that regulate ENaC is SGK. This Figure 10 MaR1 improved AFC through activating the ALX/PI3K /AKT/Need4-2 pathway in vivo. MaR1 (200 ng/kg) and BOC-2 (600ng/kg), LY294002 (3 mg/kg) were co-administered to Sprague-Dawley rats through caudal vein 8 h after LPS (14 mg/kg) was administered, and intratracheal instillation of 5% albumin solution containing Evans Blue-labeled albumin (5 ml/kg) through a tracheostomy to the left lung; AFC was measured over 60 min in ventilated animals (c). Expression of phosphorylated Akt and phosphorylated SGK1 in rat lung 8 h after LPS-induced actue lung injury or saline treatment were measured by western blotting. Western blot data were replicated 43 times. The band intensity of phosphorylated Akt (a) and phosphorylated SGK1 (b) were quantitated by normalized for total Akt and total SGK1, respectively, and expressed as fold of the control. Expression of Nedd4-2 in rat lung 8 h after LPS-induced acute lung injury or saline treatment were measured by western blotting. Western blot data were replicated 43 times. The band intensity of Nedd4-2 quantitated by normalized for β-actin and expressed as fold of the control (d). Data are presented as mean ± s.e.m. n = 8. **Po0.01 versus control group; ## Po0.01 versus LPS group; && Po0.01 versus LPS+MaR1 group.
Maresin1 stimulates alveolar fluid clearance J-L Zhang et al kinase is known to be a key mediator of the effect of the hormone aldosterone on ENaC. 50 Our studies revealed that p-Akt (ser 473 ) was decreased after LPS stimulation and MaR1 reversed the decreased of p-Akt (ser 473 ), but the beneficial effects were abrogated by BOC-2 and LY294002. However, MaR1 had no effect on the expression of SGK1 (ser 422 ). Furthermore, LY294002 blocked AFC stimulated by MaR1. The implication for our work is that MaR1 promoted AFC by activating p-Akt via PI3K but not p-SGK1.
Nedd4-2, an E3 ubiquitin-protein ligase, which has been shown to negatively regulate ENaC expression in vitro and in vivo. 51, 52 Recent studies using Nedd4-2-deficient mice clearly demonstrated that Nedd4-2, which is co-expressed with ENaC in lung epithelial cells transporting Na + , has a crucial role in the regulation of ENaC activity in the lung. 53 It was shown that AKT increases ENaC activity by phosphorylation of Nedd4-2, thereby reducing the affinity of Nedd4-2 to ENaC. 49 One study indicated that reducing the ENaC/ Nedd4-2 interaction results in an increase in the open probability of the channel. 54 Another study revealed that phosphorylation of Nedd4-2 by Akt reduces the ability of Nedd4-2 to suppress surface expression of ENaC, consequently allowing Na + absorption to increase. 48 Consistently, we also found MaR1 inhibited the increase of Nedd4-2 protein expression induced by LPS, the beneficial effect of MaR1 on reducing Nedd4-2 protein expression was abolished by BOC-2 and LY294002 in vivo. The results show that the MaR1 response is ALX/ PI3K/Nedd4-2 dependent. The key role for MaR1 during LPS-induced ALI in vivo and in vitro is summarized in Figure 11 .
In conclusion, these data demonstrate that MaR1 alleviated pulmonary edema, enhanced AFC, and attenuated lung injury partially through stimulation of ENaC and Na,K-ATPase via activation of the ALX/PI3K/Nedd4-2 pathway in LPS-induced ALI. Thus, treatment with MaR1 in critically ill patients with ALI has the potential to augment lung edema clearance. More importantly, MaR1 is endogenous chemical mediators during the resolution of inflammation. So, it maybe has fewer side effects. Our findings reveal a novel mechanism for pulmonary edema fluid reabsorption and MaR1 may provide a new therapy for the resolution of ALI/ARDS.
